Opioids

Clinical Anesthesia: Seventh Edition

Volumn , Issue , 2013, Pages

  Dahan, Albert ^a   Niesters, Marieke ^a   Olofsen, Erik ^a   Smith, Terry ^a   Overdyk, Frank ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84976590538     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (161)

1. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Int Med. 2010;152:85.
2. Vila H Jr, Smith RA, Augustyniak MJ, et al. The efficacy of pain management before and after implementation of hospital-wide pain management standards: Is patient safety compromised by treatment solely based on numerical pain ratings? Anesth Analg. 2005;101:474.
3. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010;363:1981.
4. Sertürner F. Uber das Morphium, eine neue salzfähige Grundlage, und die Mekonsäure, als Hauptbestandtheile des Opiums. Ann Physik. 1917;5:56.
5. Huxtable RJ, Schwartz SK. The isolation of morphine. Mol Interv. 2001;1:189.
6. Bovill JG. Opium: A drug ancient and modern. In: Dahan A, van Kleef JW eds. Advances in Anesthesia and Analgesia. Leiden: University Medical Center; 2007; 1:13.
7. Garfield E. The 1982 John Scott Award goes to Jack Fishman and Harold Blumberg for synthesis and investigation of naloxone. Essays Inform Sci. 1983;6:121.
8. Tzschentke TM, Jahnel U, Kögel B, et al. Tapentadol hydrochloride: A next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today. 2009;45:483.
9. Hatrick CT, Rozek RJ. Tapentadol in pain management: A μ-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs. 2011;25:359.
10. Kieffer BL, Gavériaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol. 2002;66:285.
11. Chiou LC, Liao YY, Fan PC, et al. Nociceptin/orphanin FQ peptide receptors: Implications' for pain and analgesia. Curr Drug Targets. 2007;8:117.
12. Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol. 1993;16:1.
13. 3 opiate receptor subtype. Pain Forum. 1999;8:206-209.
14. Alexander SPH, Mathie A, Peters JA. Guide to receptors and channels (GRAC), 4th Edn. Br J Pharmacol. 2009;158(suppl 1):S1.
15. Standifer KM, Pasternak GW. G proteins and opioid receptor-mediated signaling. Cell Signal. 1997;9:237.
16. Sacerdote P. Opioids and the immune system. Pall Med. 2006;20:s9-s16.
17. Glattard E, Muller A, Aunis D, et al. Rethinking the opiate system? Morphine and morphine 6 glucuronide as new endocrine and neuroendocrine mediators. Med Sci Monit. 2006;12:SR25.
18. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Ann Rev Biochem. 2004;73:953.
19. Chen YL, Law PY, Loh HH. The other side of the opioid story: Modulation of cell growth and survival signaling. Curr Med Chem. 2008;15:772.
20. Eguchi M. Recent advances in selective opioid receptor agonists and antagonists. Med Res Rev. 2004;24:182.
21. Bovill JG. Surgery for cancer: Does anesthesia matter? Anesth Analg. 2010;110:1524.
22. Matthes HWD, Maldonado R, Simonin F, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid receptor gene. Science. 1996;383:819.
23. Kitchen I, Slowe SJ, Matthes HW, et al. Quantitative autoradiographic mapping of mu-, delta-and kappa-opioid receptors in knockout mice lacking the mu-opioid receptor gene. Brain Res. 1997;778:73.
24. Dahan A, Sarton E, Teppema L, et al. Anesthetic potency and influence of morphine and sevoflurane on respiration in μ-opioid receptor knockout mice. Anesthesiology. 2001;94:824.
25. Romberg R, Sarton E, Teppema L, et al. No difference between morphine and morphine-6-glucuronide on respiration in μ-opioid receptor deficient mice. Br J Anaesth. 2003;91:862.
26. Lutfy K, Eitan S, Bruyant CD, et al. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci. 2003;23:10331.
27. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96:627.
28. Callahan RJ, Au JD, Paul M, Liu C, et al. Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in Xenopus oocytes: Stereospecific and subunit effects. Anesth Analg. 2004;98:653.
29. Dykstra LA, Fischer FB, Balter RE, et al. Opioid antinociception, tolerance and dependence: Interactions with the N-methyl-D-aspartate system in mice. Behav Pharmacol. 2011;22:540.
30. Kissin I, Bright CA, Bradley L. The effect of ketamine on opioid-induced acute tolerance: Can it explain reduction of opioid consumption with ketamine-opioid analgesic combinations? Anesth Analg. 2000;91:148.
31. Reeves RR, Burke RS. Tramadol: Basic pharmacology and emerging concepts. Drugs Today. 2008;44:827.
32. Sarton E, Teppema L, Olievier C, et al. Involvement of μ-opioid receptor in ketamine-induced respiratory depression and antinociception. Anesth Analg. 2001;93:1495.
33. Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355f.
34. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest. 2010;120:3779.
35. Brown EN, Purdon PL, Van Dort CJ. General anesthesia and altered states of arousal: A systems neuroscience analysis. Ann Rev Neurosci. 2011;34:601.
36. Fields HL. Pain modulation: Expectation, opioid analgesia and virtual pain. Prog Pain Res. 2000;122:245.
37. Butler RK, Finn DP. Stress-induced analgesia. Prog Neurobiol. 2009;88:184.
38. Eipert F, Bingel U, Schoell ED, et al. Activation of opioidergic descending pain control system underlies placebo analgesia. Neuron. 2009;63:533.
39. Pud D, Granovsky Y, Yarnitsky D. The methodology of experimentally-induced diffuse noxious inhibitory (DNIC)-line effects in humans. Pain. 2009;144:16.
40. Beecher HK. Pain in men wounded in battle. Ann Surg. 1946;123:96.
41. Zubieta J-K, Bueller JA, Jackson LR, et al. Placebo effects mediated by endogenous opioid activity on μ-opioid receptors. J Neurosci. 2005;25:7754.
42. Wager TD, Rilling JK, Smith EE, et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science. 2004;303:1162.
43. Petrovic P, Kalso E, Petersson KM et al. Placebo and opioid analgesia - imaging a shared neuronal network. Science. 2002;295:1737.
44. Moont R, Pud D, Sprecher E, et al. "Pain inhibits pain" mechanisms: Is pain modulation simply due to distraction. Pain. 2010;150:113.
45. Niesters M, Dahan A, Swartjes M, et al. Effect of ketamine on endogenous pain modulation in healthy volunteers. Pain. 2010;152:656.
46. Scholz J, Woolf CJ. The neuropathic pain triad, neurons, immune cells and glia. Nature Neurosci. 2007;10:1361.
47. Kapitzke D, Vetter I, Cabot PJ. Endogenous opioid analgesia in peripheral tissues and the implications for pain control. Ther Clin Risk Manag. 2005;1:279.
48. Stein S, Halina M. Modulation of peripheral sensory information by the immune system: Implication for pain therapy. Pharmacol Rev. 2011;63:860.
49. Busch-Dienstfertig M, Stein C. Opioid receptors and opioid peptide-producing leucocytes in inflammatory pain - basic and therapeutic aspects. Brain Beh Immun. 2010;24:683.
50. Bekhit MH. Opioid-induced hyperalgesia and tolerance. Am J Therapeut. 2010;17:498.
51. Bruno G, Bossard AE, Coste C, et al. Acute opioid tolerance: Intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000;93:409.
52. Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology. 2005;103:147.
53. van Dorp ELA, Kest B, Kowalczyk WJ, et al. Morphine-6-glucuronide rapidly increases pain sensitivity independently of opioid receptors in mice and humans. Anesthesiology. 2009;110:1356.
54. Juni A, Cai M, Stamkova M, et al. Sex-specific mediation of opioid-induced hyperalgesia by the melanocortin-1 receptor. Anesthesiology. 2010;112:181.
55. Waxman AR, Arout C, Caldwell M, et al. Acute and chronic fentanyl administration causes hyperalgesia independently of opioid receptor activity in mice. Neurosci Lett. 2009;468:68.
56. Bohn LM, Lefkowitz RJ, Gainetdinov RR, et al. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science. 1999;286:2495.
57. Zuo Z. The role of opioid receptor internalization and beta-arrestins in the development of opioid tolerance. Anesth Analg. 2005;101:728.
58. Narinder P. Opioids in acute pain. In: Stein C, ed. Opioids in Pain Control, Basic and Clinical Aspects. Cambridge, UK: Cambridge University Press; 1999:247.
59. Franson HE. Postoperative patient-controlled analgesia in the pediatric population: A literature review. AANA J. 2010;78:374.
60. Hughes MA, Glass PSA, Jacobs JR. Context-sensitive half-time in multicompartment: Pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology. 1992;76:334.
61. Kapila A, Glass PSA, Jacobes JR, et al. Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology. 1995;83:968.
62. Olofsen E, Boom M, Nieuwenhuijs D, et al. Modeling the non-steady-state respiratory effects of remifentanil in awake and propofol sedated healthy volunteers. Anesthesiology. 2010;212:1382.
63. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211.
64. Smith HS. The metabolism of opioid agents and the clinical impact of their active metabolites. Clin J Pain. 2011;27:824.
65. Christrup LL. Morphine metabolites. Acta Anaesthesiol Scand. 1997;41:116.
66. van Dorp E, Romberg R, Sarton E, et al. Morphine-6-glucuronide: Morphine's successor for postoperative pain relief? Anesth Analg. 2006;102:1.
67. Romberg R, Olofsen E, Sarton E, et al. Pharmacokinetic/pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: Absence of sex differences. Anesthesiology. 2004;100:120.
68. Zelcer N, van de Wetering K, Hillebrand M, et al. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and decreased antinociception by morphine-6-glucuronide. Proc Natl Acad Sci USA. 2005;102:7274.
69. Lötsch J, Zimmermann M, Darimont J, et al. Does the A118G polymorphism at the μ-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology. 2002;97:814.
70. Tateishi T, Krivoruk Y, Ueng YF, et al. Identification of liver cytochrome P-450 3 A as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg. 1996;82:167.
71. Klees TM, Sheffels P, Dale O, et al. Metabolism of alfentanil by cytochrome P4503 A (CYP3 A) enzymes. Drug Metab Dispos. 2005;33:303.
72. Klees TM, Sheffels P, Thummel KE, et al. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology. 2005;102:550.
73. Scott LJ, Perry CM. Spotlight on remifentanil for general anesthesia. CNS Drugs. 2005;19:1069.
74. Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application. Anesthesiology. 1997;86:24.
75. Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology. 1997;86:10.
76. Egan TD, Minto CF, Hermann DJ, et al. Remifentanil versus alfentanil: Comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology. 1996;84:821.
77. Totah RA, Sheffels P, Whittington D, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology. 2008;108:363.
78. Kharasch E. Intraoperative methadone: Rediscovery, reappraisal and reinvigoration. Anesth Analg. 2011;112:13.
79. van Dorp E, Yassen A, Dahan A. Naloxone treatment in opioid addiction: The risks and benefits. Exp Opin Drug Safe. 2007;6:125.
80. Martini C, Olofsen E, Yassen A, et al. Pharmacokinetic-pharmacodynamic modeling in acute and chronic pain: An overview of the recent literature. Exp Rev Pharmacother. 2011;4:719.
81. Segre G. Kinetics of interaction between drugs and biological systems. Farmaco Sci. 1968;23:907.
82. Hull CJ. Pharmacokinetics and pharmacodynamic. Br J Anaesth. 1979;51:579.
83. Sheiner L, Stanski LB, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin Pharmacol Ther. 1979;25:358.
84. Dahan A, Romberg R, Teppema L, et al. Simultaneous measurement and integrated analysis of analgesia and respiration after an intravenous morphine infusion. Anesthesiology. 2004;101:1201.
85. Aubrun F, Salvi N, Coriat P, et al. Sex-and age-related differences in morphine requirements for postoperative pain relief. Anesthesiology. 2005;103:156.
86. Scott JC, Cooke JE, Stanski DR. Electroencephalographic quantitation of opioid effect: Comparative pharmacodynamics of fentanyl and sufentanil. Anesthesiology. 1991;74:34.
87. Scott JC, Ponganis KV, Stanski DR. EEG quantitation of narcotic effect: The comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 1985;62:234.
88. Dahan A, Boom M, Olofsen E. Differences in onset/offset times for different end-points: Pain relief, pupil size and respiratory depression. Anesthesiology. 2011;A1569.
89. Olofsen E, Romberg R, Bijl H, et al. Alfentanil and placebo analgesia: Absence of sex differences. Anesthesiology. 2005;103:130.
90. Aubrun F, Langeron O, Quesnel C, et al. Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. Anesthesiology. 2003;98:1415.
91. Sarton E, Olofsen E, Romberg R, et al. Sex differences in morphine analgesia: An experimental study in healthy volunteers. Anesthesiology. 2000;93:1245.
92. Abou Hammoud H, Simon N, Urien S, et al. Intravenous morphine titration in immediate postoperative pain management: Population kinetic-pharmacodynamic and logistic regression analysis. Pain. 2009;144:139.
93. Mazoit JX, Btscher K, Samii K. Morphine in postoperative patients: Pharmacokinetics and pharmacodynamics of metabolites. Anesth Analg. 2007;105:70.
94. Tallarida RJ, Stone DJ, McCary JD, et al. Response surface analysis of synergism between morphine and clonidine. J Phramacol Exp Ther. 1999;289:8.
95. Schulte H, Sollevi A, Sgerdahl M. The synergistic effect of combined treatment with systematic ketamine and morphine on experimentally induced wind-up pain in humans. Anesth Analg. 2004;98:1574.
96. Daniel M, Weiskopf RB, Noorani M, et al. Fentanyl augments the blockade of the sympathetic response to incision (MAC-BAR) produced by desflurane and isoflurane. Anesthesiology. 1998;88:43.
97. Kazama T, Ikeda K, Morita K. The pharmacodynamic interaction between propofol and fentanyl with respect to suppression of somatic or hemodynamic responses to skin incision, peritoneum incision, and abdominal wall retraction. Anesthesiology. 1998;89:894.
98. Sebel PS, Glass PSA, Fletcher JE, et al. Reduction of the MAC of desflurane with fentanyl. Anesthesiology. 1992;88:43.
99. Katoh T, Ikeda K. The effects of fentanyl on sevoflurane requirements for loss of consciousness and skin incision. Anesthesiology. 1998;88:18.
100. Nelson L, Schwaner R. Transdermal fentanyl: Pharmacology and toxicology. J Med Toxicol. 2009;5:230.
101. Anonymous. Fentanyl patches: Preventable overdose. Prescrire Int. 2010;19:22.
102. Biedrzycki OJ, Bevan D, Lucas S. Fatal overdose due to prescription fentanyl patches in a patient with sickle cell/beta-thalassemia and acute chest syndrome: A case report and review of the literature. Am J Forensic Med. 2009;30:188.
103. Babenco HD, Conard PF, Gross JB. The pharmacodynamic effect of a remifentanil bolus on ventilatory control. Anesthesiology. 2000;92:393.
104. Drover D, Lemmens HJM. Population pharmacodynamics and pharmacokinetics of remifentanil as a supplement to nitrous oxide anesthesia for elective abdominal surgery. Anesthesiology. 1998;89:869.
105. Mertens M, Olofsen E, Engbers F, et al. Propofol reduces perioperative remifentanil requirements in a synergistic manner. Response surface modeling of perioperative remifentanil-propofol interactions. Anesthesiology. 2003;99:347.
106. Lang E, Kapila A, Schlugman D, et al. Reduction of isoflurane minimal alveolar concentration by remifentanil. Anesthesiology. 1996;85:721.
107. Klepstad P, Fladvad T, Skorpen F, et al. Influence from genetic variability on opioid use for cancer pain: A European genetic association study of 2294 pain patients. Pain. 2011;152:1139.
108. Mogil J, Ritchie J, Smith SB, et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet. 2005;42:583.
109. Liem EB, Lin CM, Suleman MI, et al. Anesthetic requirement is increased in redheads. Anesthesiology. 2004;101:279.
110. Weinshiliboum R. Inheritance and drug response. N Engl J Med. 2003;348:529.
111. Ciszkowski C, Madadi P, Phillips MS, et al. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med. 2009;361:827.
112. Gasche Y, Daali Y, Fahti M, et al. Codeine intoxication with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351:2827.
113. Koren G, Cairns J, Gaedigk A, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006;368:704.
114. Park HJ, Shinn HK, Ryu SH, et al. Genetic polymorphism in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther. 2007;81:539.
115. Dahan A, Aarts L, Smith TW. Incidence, reversal and prevention of opioid-induced respiratory depression. Anesthesiology. 2010;112:226.
116. Hanna MH, Elliott KM, Fung, M. Randomized, double-blind study of the analgesic efficacy of morphine-6-glucuronide versus morphine sulfate for postoperative pain in major surgery. Anesthesiology. 2005;102:815.
117. Chung F, Yegneswaran B, Liao P, et al. Stop questionnaire: A tool to screen for obstructive apnea. Anesthesiology. 2008;108:812.
118. Overdyk FJ, Hillman DR. Opioid modeling of central respiratory drive must take upper airway obstruction into account. Anesthesiology. 2011;114:219.
119. Bernards CM, Knowlton SL, Schmidt DF, et al. Respiratory and sleep effects of remifentanil in volunteers with moderate obstructive sleep apnea. Anesthesiology. 2009;110:41.
120. Wu A, Drummonmg GB. Sleep arousal after lower abdominal surgery and relation to recovery from respiratory obstruction. Anesthesiology. 2003;99:1295.
121. Dahan A. Influence of anesthesia and analgesia on the control of breathing. Br J Anaesth. 2003;91:40.
122. Chung F. http://anesthesiaandsleep.org/wp-content/uploads/2011/11/2011-Program-and-Speaker-Abstracts.pdf
123. Stone JG, Cozine KA, Wald A. Nocturnal oxygenation during patient-controlled analgesia. Anesth Analg. 1999;89:104.
124. Fu ES, Downs JB, Schweiger JW, et al. Supplemental oxygen impairs detection of hypoventilation by pulse oximetry. Chest. 2004;126:1552.
125. Lötsch J, Dudziak R, Freynhagen R, et al. Fatal respiratory depression after multiple intravenous morphine injections. Clin Pharmacokinet. 2006;45:1051.
126. Pattinson KTS. Opioids and the control of breathing. Br J Anaesth. 2008;106:347.
127. Smith JC, Ellenberger HH, Ballanyi K, et al. PreBötzinger complex: A brainstem region that may generate respiratory rhythm in humans. Science. 1991;254:726.
128. Cullberg M, Eriksson YGF, Wåhlander K, et al. Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther. 2005;77:279.
129. Yassen A, Olofsen E, Dahan A, et al. Pharmacokinetic-pharmacodynamic modeling of the efficacy and safety of buprenorphine in rats. Pharm Res. 2008;25:183.
130. Olofsen E, van Dorp E, Teppema L, et al. Naloxone reversal of morphine and morphine-6-glucuronide-induced respiratory depression in healthy volunteers. Anesthesiology. 2010;112:1417.
131. van Dorp E, Yassen A, Sarton E, et al. Naloxone-reversal of buprenorphine-induced respiratory depression. Anesthesiology. 2006;105:51.
132. Amin HM, Sopchak AM, Esposito BF, et al. Naloxone-induced and spontaneous reversal of depressed ventilatory response to hypoxia during and after continuous infusion of remifentanil or alfentanil. J Pharmacol Ther. 1995;274:34.
133. Curry JP, Lynn LA. Threshold monitoring, alarm fatigue, and the patterns of unexpected hospital death. APSF Newsletter. 2011;26(Fall issue):32 (http://www.apsf.org/newsletters/html/2011/fall/07_threshold.htm).
134. Smith I, Mackay J, Fahrid N. Respiratory rate measurement: A comparison of methods. Br J Healthcare Assistants 2011;5:18.
135. Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004;350:2441.
136. Macario A, Weinger N, Truong P, et al. Which clinical anesthesia outcomes are both common and important to avoid? Anesth Analg. 1999;88:1085.
137. Gan TJ. Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist-based pharmacotherapy. CNS Drugs. 2007;21:813.
138. Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: Prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181.
139. Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage. 2008; 35:103.
140. Thompson DR. Narcotic analgesic effects on the sphincter of Oddi: A review of the data and therapeutic implications in treating pancreatitis. Am J Gastroenterol 2001;96:1266.
141. Verhamme KM, Strurkenboom MC, Stricker BH, et al. Drug-induced urinary retention: Incidence, management and prevention. Drug Saf. 2008;31:373.
142. Rosow CE, Gomery P, Chen TY, et al. Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin Pharmacol Ther. 2007;82:48.
143. Bennet JA, Abrams JT, Van Riper DF, et al. Difficult or impossible ventilation after sufentanil-induced anesthesia is caused primarily by vocal cord closure. Anesthesiology. 1997;87:1070.
144. Blunk JA, Schmelz M, Zeck S, et al. Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: An in vivo microdialysis study in human skin. Anesth Analg. 2004;98:364.
145. Schmelz M. A neural pathway for itch. Nat Neurosci. 2001;4:9.
146. Miayamoto T, Patapoutian A. Why does morphine make you itch? Cell. 2011; 147;261.
147. Ganesh A, Maxwell LG. Pathophysiology and management of opioid-induced pruritus. Drugs. 2007;67:2323.
148. Kharasch ED, Francis A, London A, et al. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3 A induction. Clin Phramacol Ther. 2011;90:100.
149. Larson MD, Berry PD. Supraspinal papillary effects of intravenous and epidural fentanyl during isoflurane anesthesia. Reg Anesth pain Med. 2000;25:60.
150. Benyamin R, Trescott AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11:S105.
151. Papaleontiou M, Henderson CR, Turner BJ, et al. Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: A systematic review and meta-analysis. J Am Geriatr Soc. 2010;58:1353.
152. DeSouza G, Lewis MC, TerRiet MF. Severe bradycardia after remifentanil. Anesthesiology. 1997;87:1019.
153. Douma M, Middeldorp A, Dahan A, et al. A comparison of remifentanil patient-controlled analgesia with epidural analgesia during labour. Int J Obstet Anesth. 2011;20:118.
154. Volmanen PVE, Akural EI, Raudaskoski T, et al. Timing of intravenous patient-controlled remifentanil bolus during early labor. Acta Anaesthesiol Scand. 2011; 55:486.
155. Leong WL, Sng BL, Sia AT. A comparison between remifentanil and meperidine for labor analgesia; a systematic review. Anesth Analg. 2011;113:818.
156. Buehner U, Broadbent JR, Chesterfield B. Remifentanil patient-controlled analgesia for labour: A complete audit cycle. Anaesth Intensive Care. 2011;39:666.
157. Niesters M, Dahan A, Kest B, et al. Do sex differences exist in opioid analgesia? A systematic review and meta-analysis of human experimental and clinical studies. Pain. 2010;151:61.
158. Zubieta JK, Dannals RF, Frost JJ. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry. 1999;156:842.
159. Dahan A, Sarton E, Olievier C. Sex-related differences in the influence of morphine on ventilatory control in humans. Anesthesiology. 1998;88:903.
160. Zun LS, Downey LV, Grossman W, et al. Gender differences in narcotic-induced emesis in the ED. Am J Emerg Med. 2002;20:151.
161. Cepeda MS, Farra JY, Baumgarten M, et al. Side effects of opioids during short-term administration: Effects of age, gender and race. Clin Pharmacol Ther. 2003; 74:102.